Copyright
©2010 Baishideng Publishing Group Co.
World J Clin Oncol. Feb 10, 2011; 2(2): 125-134
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.125
Figure 7 National Surgical Adjuvant Study for Breast Cancer 01 Trial.
Relapse-free survival (RFS) (A) and overall survival (OS) (B) of patients treated with tegafur/uracil (UFT) or chemotherapy (CMF). A: 5-year; 87.8% vs 88.0%; hazard ratio (HR) = 0.98; 95% CI: 0.66-1.45. (Source: Figure 3A in reference 7); B: 5-year, 96.2% vs 96.0%, HR = 0.81, 95% CI: 0.44-1.48. (Source: Figure 3B in reference 7).
- Citation: Park Y, Kitahara T, Takagi R, Kato R. Current status of therapy for breast cancer worldwide and in Japan. World J Clin Oncol 2011; 2(2): 125-134
- URL: https://www.wjgnet.com/2218-4333/full/v2/i2/125.htm
- DOI: https://dx.doi.org/10.5306/wjco.v2.i2.125